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Background: Repetitive long-term Vaccinia Melanoma Cell Lysate (VMCL) vaccination schedules have proved clinically
effective in producing Complete Responses and strong durable survivals for up to 6.1 years in a previous study of
patients with advanced Stage IV and Stage IIIc melanoma. These studies were expanded to include 54 patients
for further evaluation of these findings.
Methods: 54 patients comprising 48 Stage IV (6 M1a, 14 M1b, 28 M1c) and 6 advanced Stage III (5 IIIc; 1 IIIb)
were studied using repeated intra-dermal VMCL vaccine therapy. If disease progressed, vaccine was continued
together with standard chemotherapy (DTIC and/or Fotemustine). Overall survival was the primary end-point
assessed, with clinical responses and toxicity recorded.
Results: From vaccine commencement, median overall survival was 14 months, ranging from 4 to 121 months.
Kaplan-Meier survival analysis demonstrated overall 1, 2 and 3-year survival estimates of 57%, 26% and 18.5%
respectively, and overall 5-year survival of 15.4%. No appreciable toxicity was observed. Complete Responses (CR)
occurred in 16.7% (9) and partial responses (PR) in 14.8% (8) of patients. Stable disease was noted in a further 25
patients (46.3%). No response to therapy was apparent in 12 patients (22.2%). The overall response rate was 31.5%
(CR + PR), with clinically significant responses (CR + PR + SD) in 77.8% of patients. Strong, durable clinical responses with
overall survivals ≥ 23 months occurred in 29.6% of patients treated with repeated VMCL vaccine for advanced
melanoma, (+/- concurrent chemotherapy).
Conclusions: Prolonged, repetitive VMCL vaccination immunotherapy appears to be a clinically effective means
of generating relatively high CR rates, useful clinical responses and long-term survivals, with little toxicity, but
remains notably under-explored. Successive immunomodulation might explain the results. Closer analysis of
repetitive dosing is required to improve clinical response rates and survival, perhaps by optimising the timing of
immunotherapy delivery.
Trial registration: Australian and New Zealand Clinical Trials Registry ANZCTRN12605000425695.
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Survival of patients with advanced disseminated melan-
oma remains poor using almost any therapeutic means
currently available. In those relatively rare situations
where surgery can be utilised in selected patients with
metachronous or synchronous metastatic melanoma de-
posits, 5-year survivals of 5-35% have been reported
[1-3]. Recent advances in transduction pathway inhib-
ition with B-raf and MEK, or immunotherapy using
CTLA-4 and PD-1/L1 inhibitory antibody therapies have
produced some encouraging results [4-14]. However, the
majority of the clinical responses have not been translat-
ing into complete responses (CR), nor long-term sur-
vivals. The currently reported best CR rates have been
associated with immunotherapies such as interleukin-2
(IL-2) (5-10%), combined IL-2 and CTLA-4 inhibitor
therapies (17%), vaccine therapy (18.9%), and cellular
therapy (22%) [8,15,16]. Vaccinia Melanoma Cell Lysate
(VMCL) vaccine therapy has been reported previously,
and the role of the immune system, vaccines and
immuno-chemotherapy have been discussed [15,17-23].
The results of an initial pilot study using repeated doses
of VMCL vaccine therapy in 37 patients with advanced
surgically non-resectable stage IV/ IIIc metastatic melan-
oma demonstrated a CR rate of 18.9%, with strong durable
survivals for up to 6.1 years, and survival rates of 40.5%,
21.6% and 10.8% at 1, 2 and 3 years respectively [15].
The primary aim of the present study was to investi-
gate overall survival, with clinical response rates and
toxicity also being evaluated, using the repetitive VMCL
vaccine therapy approach, in a larger cohort of 54 pa-
tients with surgically non-resectable advanced Stage IV/
III in-transit metastatic melanoma.
Methods
Patients and inclusion/exclusion criteria
Informed consent was obtained before entry into the study,
which was approved by the Royal Adelaide Hospital
Human Research Ethics Committee and was registered
with the Australian Clinical Trials Registry [ACTRN
12605000425695]. 54 stage IV/IIIc advanced melanoma pa-
tients were enrolled in these studies for the primary aim.
Most patients had failed other therapies. Confidentiality of
patient data was preserved. Overall quality of life was mea-
sured by assessing functional status using the standard
Eastern Cooperative Oncology Group (ECOG) and Union
for International Cancer Control (UICC) scores. CT scans
were performed each 3 months and ophthalmology exami-
nations (for possible melanoma associated retinopathy/
iritis) each year, or as clinically indicated.
Inclusion criteria
Patients ≥ 18 years of age; ECOG 0-2; evaluable metasta-
ses from primary cutaneous melanoma; advanced non-surgically resectable AJCC Stage IV or Stage IIIb/c
disease; tumour volume < 20 cm diameter or < 70% of
organ replacement; +/- post-surgical treatment of brain
metastases; voluntary informed consent.
Exclusion criteria
Second primary invasive cancer (not BCC, SCC of skin
or resected in-situ malignancy); untreated brain metasta-
ses, extremely extensive metastatic disease, bone metas-
tases only; high-dose oral steroid therapy; pregnant or
lactating; severely atopic individuals; severe cachexia; im-
munodeficiency; HIV, Hepatitis B or C positive. Three
patients with inoperable brain metastases were excluded.
No patient was both eligible and refused to participate.
VMCL vaccine
Vaccinia Melanoma Cell Lysate (VMCL) vaccine was
manufactured using successive aliquots of a single
stable culture seed lot of the allogeneic melanoma cell
line MM200, which were thawed as required, briefly
cultured then infected with vaccinia virus (CSL laborator-
ies, Melbourne) to cause cell lysis. The thawed MM200
aliquots were determined to be stable over time using
karyotype, western blot and antigenic analysis. Lysed cells
were ultrasonicated and centrifuged to create the allogen-
eic cell lysate vaccine product for use as described previ-
ously [15,17-20]. Each vaccine had a protein content of
100mcg per 0.3 ml dose, equivalent to 5 × 106 cells per
dose. Vaccine doses were frozen to preserve protein con-
tent at -20°C and thawed to room temperature before use.
The process had been previously used successfully in a
previous Australian randomised clinical trial for earlier-
stage, completely resected high-risk melanoma [20].
VMCL vaccinations
All patients received regular 2-weekly single-dose intra-
dermal vaccinations for 6 months; then monthly for
6 months; then if stabilisation or a CR was obtained, 3-
monthly thereafter. Injection sites were rotated between
upper outer aspects of all 4 limbs, but avoiding any limb
where lymph node dissection was performed. Previous
VMCL studies using 0.3 ml of re-suspended sonicated
lysate had determined safety and efficacy of this dose
and schedule [15,17-20,24]. Occasional minimal skin re-
actions were noted in the pilot or previous studies, and
precautionary resuscitation facilities were available (but
never required) with patients being observed for 30 minutes
after each vaccination.
Chemotherapy
Melanoma disease progression during vaccine therapy
indicated addition of concurrent standard chemotherapy
(either dacarbazine (DTIC) 1000 mg/m2 at 3-weekly inter-
vals intravenously), or fotemustine (100 mg/m2 weekly
Table 1 Characteristics for the 54 patients entered into
the study
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[25,26]. Vaccinations were maintained at 2-weekly in-
tervals throughout the chemotherapy period, including
between doses and during breaks in chemotherapy.
Occasional vaccine schedule adjustment was required
to suit the chemotherapy schedule.
Skin Delayed Type Hypersensitivity (DTH)
The 1st and the 4th VMCL vaccination doses (0.3 ml)
were investigated to examine DTH responses. Each read-
out was 48 hours after vaccine administration. Erythema
and the induration were recorded and independently
recorded in two directions perpendicular to each other.




Overall survival was assessed by survival in months
from the time of commencement of vaccination to the
date of analysis or death of the patient.
Secondary end-points
(i) Toxicity and tolerability: local or systemic reactions
were recorded.
(ii) Tumour response rates: Rates of Complete Response
(CR), Partial Response (PR), Stable Disease (SD) and
Progressive Disease (PD) were recorded using the WHO cri-
teria [27]. Observable subcutaneous lesions were assessed
using direct size measurement using calipers or a ruler,
and internal metastases were assessed using CT scans
at 3-monthly intervals or as clinically otherwise deter-
mined, and where appropriate using ultrasound, MRI
or Positron Emission Tomographic (PET) scans. Mea-
surements were in two directions perpendicular to each
other.
Statistical analysis
This was performed using mean and median calcula-
tions, Kaplan-Meier analysis and time series analysis
with the assistance of statisticians and a mathematician
(TS; NB; AC). A significance level of p < 0.05 was set for
all analyses.
Results
Data for these results were collected from enrolment of
the first patient in November 2000, until data analysis of
54 patients at the end of 2010. The period from the date
of vaccination commencement of the first patient to the
end 2010 was 10 years and 1 month (3690 days).
Patient characteristics
The median age of the 54-melanoma patients enrolled in
the study was 66 years (range 35-97), the majority ofwhom had Stage IV disease. Other demographic/classifi-
cation data are demonstrated in Table 1.
Primary endpoint – overall survival
Overall survival (to either death or the date of analysis)
for all 54 patients ranged from 4 months to 121 months.
Median survival was 14 months, with a mean survival of
22.5 months. A Kaplan-Meier survival analysis was per-
formed which demonstrated overall 1, 2 and 3-year sur-
vival estimates of 57%, 26% and 18.5% respectively. The
overall 5-year survival estimate was 15.4%. These are as
shown in Figure 1.
Survival duration and treatment type patterns are also
shown in Figure 2 to further illustrate patient responses.
At analysis, an observed survival of 12 months or
more occurred in 55.6% or 30 of the 54 patients.
Survival greater than 23 months occurred in 29.6%
(16) of the 54 patients, ranging from 1.9 years to
10.1 years. Of those 16 patients, organ +/- lymph node
metastases were present in 10 patients (62.5%).
Multiple subcutaneous/cutaneous metastases alone oc-
curred in the remaining 6 patients (37.5%). Characteris-
tics of these 16 patients are shown in Table 2.
For the entire group, at the end of the survey period, 9
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Figure 1 Kaplan-Meier survival curve for VMCL Treated Patients
(n = 54).
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the completion of study period. The median (mean) sur-
vival time of the 9 patients alive was 61 (67) months
from vaccine commencement.
Clinical disease responses
Complete Responses occurred in 16.7% (9) and partial
response (PR) in 14.8% (8) patients. Stable disease wasFigure 2 Individual patient survival and treatment data to December
time is to follow-up or death; vaccine is VMCL; Chemotherapy is systenoted in a further 25 patients (46.3%). In 12 patients
(22.2%) no response to therapy was apparent. The over-
all response rate was 31.5% (CR + PR), with clinically sig-
nificant responses (CR + PR + SD) in 77.8% of patients.
Of the complete responders, complete durable regres-
sion of all disease beyond 18 months (alive + CR) oc-
curred in 7 patients (12.9%).
Of the 9 (16.7%) CR’s that occurred, 5 were in patients
who received VMCL vaccine alone, and 4 had vaccine
with systemic chemotherapy.
Responses were sometimes associated with quite re-
markable regression of large masses of tumour as shown
in Figure 3.
Toxicity
No toxicity issues pertaining to VMCL vaccine adminis-
tration alone were experienced. Any reported toxicities
were related to known standard chemotherapy side effects
and appeared unaffected by concomitant vaccination.
Delayed Type Hypersensitivity (DTH)
There were no significant DTH responses observed.
Prior clinical treatment type
All patients had some form of surgery prior to their
entry into the trial. This ranged from surgery for initial2010 (n = 54) [Korn line is survival data from Korn et al., [28];
mic chemotherapy].
Table 2 Clinical outcome details for 16 patients surviving
≥ 23 months including survival times (to follow-up at end
2010 or death) in months, disease sites at commencement
of vaccination, treatments prior to commencement of
vaccination and current status
Survival
(Months)
ID Disease sites Prior
Tx
Status
121 015 s/c, LN S, R Alive, fully functional
117 002 S/C, lung, LN S, B Alive, fully functional
93 010 s/c S, ILI Alive, fully functional
76 021 s/c S, ILI Alive, fully functional
61 031 s/c, lung, LN S, R Alive, fully functional
44 008 s/c S Died
35 049 s/c, lung S AWD, fully functional
34 050 s/c, LN, brain, spleen R, S Alive, fully functional
34 046 s/c, lung S Died
33 053 s/c, lung S Alive, fully functional
29 023 S/C, GB, lung S Died
27 052 s/c, umbilical S Off trial/died
26 045 s/c S Died
24 006 s/c S Died
24 017 s/c, LN, lung, liver, spleen S Died
23 009 S/C, Bone, lung S, R Died
Abbreviations: s/c sub-cutaneous, LN lymph nodes, GB gall bladder, S surgery,
B biological therapy, ILI isolated limb infusion (of chemotherapy), R radiotherapy,
AWD alive with disease.
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gional or systemic metastatic disease control.
Prior treatments (excluding surgery) occurred in 32
patients included chemotherapy and/or radiotherapy or
experimental biological therapies (6 patients: C-vax (x2
BCG-Placebo; x1 BCG±C-Vax), Heat shock protein (x1),
NYESO-Iscom matrix (x1); IL-18 (x1)). 22 patients did
not receive any prior therapy. From commencement on
the trial, 14 patients received vaccine therapy alone, ofa
Figure 3 Effects of VMCL vaccine alone on a patient treated from Aug
b) using repetitive dosing. She was able to walk after the therapy and th
improvement in self-care and walking ability. (reproduced with permissionwhich 8 had received no previous therapy. As part of the
study, 31 patients received systemic chemotherapy in
addition to the VMCL vaccine therapy.
Discussion
The CR rates and long-term survivals using the VMCL
vaccine approach are appreciable, even when compared
with newer ‘targeted’ agents, indicating that prolonged,
repetitive vaccination approaches require further de-
tailed evaluation. Although several promising newer
therapies have increased the armamentarium for man-
agement of advanced stage IV and stage III melanoma,
notably B-raf, MEK, CTLA-4 and PD-1/PDL-1 inhibi-
tory therapies, there has remained little progress in the
development of treatments that induce complete re-
sponses and long-term survival for melanoma patients
[4-14]. The reported complete response rates for B-raf
therapies was 3-6%; ipilimumab, 0.9-1.5%; combined
Braf/Mek, 2%; and PD-1, 1%; PDL-1, 6%; and CTLA-4/
PD-1, 9.6% [4-14]. These CR rates have unfortunately
not yet translated into durable cure rates with long-term
disease free 5- and 10-year survivals. A recent meta-
analysis of 38 targeted therapies has sparked editorial
comments concerning the efficacy and toxicity of nu-
merous ‘targeted’ agents, questioning the selectivity due
to ‘off-target’ effects and the level of clinical efficacy
given their presumed specificity [29,30].
Clearly, there is a current need for improvement in
both complete response rates and survival times for pa-
tients with advanced melanoma.
The current extended study results in 54 melanoma
patients compared favourably with those previously de-
scribed above (for 37 patients [15]) demonstrating rates
of CR 16.7%; PR 14.8%; ORR of 31.5%, SD in 46.3%, with
any clinically meaningful response (CR + PR + SD) in
77.8% of patients.
The primary endpoint of survival was notable using
the repetitive VMCL vaccine therapeutic approach. Theb
ust 2005 (before therapy; a) to December 2005 (during therapy;
e tumour size, pain, and odour decreased, with substantial
Journal of Cancer Therapy© [15]).
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15.4%, which is itself significant, with the longest sur-
vivor currently alive at 10.1 years duration. The fact that
29.6% (16) of the 54 patients survived 23 months or lon-
ger is of significance also. Survival times within that
group ranging from 1.9 years to 10.1 years are remark-
able, indicating that survival could be considerably pro-
longed, compared with essentially all other treatments
reported to date. Our overall survival data at 3-years
using VMCL compared favorably with some recent pre-
liminary results using pooled analysis of CTLA-4 anti-
body therapy, although the CR rate with VMCL therapy
appeared appreciably higher than for CTLA-4 therapy
[31].
The resurgence of interest in immunotherapeutic
methods (e.g. IL-2, CTLA4, PD-1, PDL-1) for the treat-
ment of metastatic melanoma and cancer in general,
opens new approaches to therapeutic design through the
better understanding of modulation of the immune sys-
tem. We reason that successive vaccination over a pro-
longed period can modulate the immune system in the
patient, with the existing non-resectable melanoma me-
tastases serving as persistent sources of tumour antigen.
This approach of repeatedly boosting or successively
immuno-modulating appears to be capable of stimulating
or ‘re-setting’ the endogenous immune response occurring
in the melanoma patient. The delivery of repeated boost-
ing signals (in the form of the VMCL vaccine) may en-
hance immune responses by better synchronisation and
coordination of the pre-existing endogenous immune re-
sponse against the tumour. Indeed, induction of allergic
tolerance, or the converse, allergic sensitisation, has been
well demonstrated for many years. It has been increasingly
appreciated and shown that repeated small doses of an
antigen can induce either tolerance or responsiveness re-
spectively, to that same antigen/allergen. The immune
system appears capable of being ‘re-educated’ to even life-
threatening bee-venom or peanut allergies by repetitive
small dose therapies in order to induce clinically effective
tolerance. The prolonged, repetitive VMCL vaccine ap-
proach we describe, might reasonably represent a reversal
of this process, to effectively induce responsiveness
through breaking tolerance. Indeed, repeated release of
tumour antigen from the cancer in vivo might be respon-
sible for systemic tolerance so widely observed in ad-
vanced cancer patients. We have previously suggested that
multiple cancer therapy approaches are able to induce im-
mune stimulation (even CR’s), and that the timing of the
delivery of the stimulus for induction of the immune re-
sponse is crucial for the immune response to be driven in
the correct direction for optimal synchronisation of an ef-
fector response. The corollary is that mis-timing could
drive the immune response in the opposite direction to in-
duce tolerance rather than responsiveness [32-34]. Thisconcept of immunotherapeutic timing and synchronisa-
tion has been extended and reviewed recently in renal cell
cancer therapy using IL-2 [35]. The recent observation of
the oscillatory behavior of the immune response against
cancer may allow better targeting of anti-cancer therapies
[32,33,36,37]. The resurgence of interest in immunother-
apies, including vaccines, may open the way for careful
immune monitoring, improved understanding of immune
modulation, and perhaps better synchronisation of therap-
ies, including combined therapies, in order to achieve im-
proved clinical responses.
Conclusions
Prolonged, repetitive VMCL vaccination immunotherapy
appears to be a clinically effective means of generating
relatively high CR rates, useful clinical responses and
long-term survivals, with little toxicity. Successive immu-
nomodulation through repetitive stimulation of the under-
lying endogenous immune response to the cancer might
explain these results. This phenomenon remains notably
under-explored. Closer analysis of repetitive dosing is re-
quired to improve clinical response rates and survival, per-
haps by optimising the timing of immunotherapy delivery.
Improved synchronisation of delivery of therapies with the
existing immune response already occurring in the pa-
tient, might offer a gentler means of successful modula-
tion of the immune response and, if true, would represent
a major advancement in cancer control.
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